Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study

INTRODUCTION: Denosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone remodeling, and an increased risk of fracture. We eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Aliya A., AbuAlrob, Hajar, M’Hiri, Iman, Ali, Dalal S., Dandurand, Karel, Said, Hosay, Alkassem, Hisham, Hakami, Yasser, Hweija, Ismail, Iqbal, Salman, Romanovschi, Mihai, Mehmood, Shehryar, Zariffeh, Heather, Guyatt, Gordon, Ibrahim, Quazi, Brignardello-Petersen, Romina, Syed, Hamza I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199867/
https://www.ncbi.nlm.nih.gov/pubmed/37186270
http://dx.doi.org/10.1007/s12020-022-03230-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199867/
https://www.ncbi.nlm.nih.gov/pubmed/37186270
http://dx.doi.org/10.1007/s12020-022-03230-5

Ejemplares similares